Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939664 | 1.00 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL789637 | 1.00 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL7531612 | 1.00 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL789155 | 1.00 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL22389997 | 1.00 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL24340313 | 0.96 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL15817493 | 0.92 | — | — | |
| SCHEMBL3814583 | 0.92 | — | — | |
| SCHEMBL8237916 | 0.90 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL6156333 | 0.90 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1078 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660069-B1 | FAST CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2024-01-03 | — | — | EP | claimed |
| EP-3569630-B1 | FAST CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2022-08-03 | — | — | EP | claimed |
| EP-3569629-B1 | FAST CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2022-07-06 | — | — | EP | claimed |
| US-11370876-B2 | Fast-curing epoxy systems | EVONIK OPERATIONS GMBH (DE) | 2022-06-28 | — | — | US | claimed |
| US-11370877-B2 | Fast-curing epoxy systems | EVONIK OPERATIONS GMBH (DE) | 2022-06-28 | — | — | US | claimed |
| CN-113861128-A | Polymerizable compound and optically anisotropic body | 江苏创拓新材料有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-111234182-A | Fast curing epoxy system | 赢创运营有限公司 | 2020-06-05 | — | — | CN | claimed |
| US-20200172723-A1 | FAST-CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2020-06-04 | — | — | US | claimed |
| EP-3660069-A1 | FAST CURING EPOXY SYSTEMS | Evonik Operations GmbH (DE) | 2020-06-03 | — | — | EP | claimed |
| US-20190352449-A1 | FAST-CURING EPOXY SYSTEMS | EVONIK DEGUSSA GMBH (DE) | 2019-11-21 | — | — | US | claimed |
| EP-2234987-A2 | PERHYDROQUINOXALINE DERIVATIVES AS ANALGESICS | Dr. August Wolff GmbH & Co. KG Arzneimittel (DE) | 2010-10-06 | — | — | EP | claimed |
| US-7759336-B2 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-20 | — | — | US | claimed |
| WO-2009080745-A2 | PERHYDROQUINOXALINE DERIVATIVES | Westfälische Wilhelms Universität Münster (DE) | 2009-07-02 | — | — | WO | claimed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | claimed |
| EP-1177190-B1 | USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI CHEM PHARM (IT) | 2005-11-02 | — | — | EP | claimed |
| JP-2002544158-A | — | — | 2002-12-24 | — | — | JP | claimed |
| US-20020161009-A1 | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | RECORDATI S.A. | 2002-10-31 | — | — | US | claimed |
| EP-1177190-A2 | USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2002-02-06 | — | — | EP | claimed |
| US-6303606-B1 | FOR THERAPY OF SEXUAL DISORDERS | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2001-10-16 | — | — | US | claimed |
| WO-2000067735-A2 | USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2000-11-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161009-A1 | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | ADRA1B, ADRA2B, ADRB2 | L3MBTL1 2916/4885ALDH1A1 687/4885PKM 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.